<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35921237</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>The contribution of brain banks to knowledge discovery in amyotrophic lateral sclerosis: A systematic review.</ArticleTitle><Pagination><StartPage>e12845</StartPage><MedlinePgn>e12845</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12845</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12845</ELocationID><Abstract><AbstractText>Over the past decade, considerable efforts have been made to accelerate pathophysiological understanding of fatal neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) with brain banks at the forefront. In addition to exploratory disease mechanisms, brain banks have aided our understanding with regard to clinical diagnosis, genetics and cell biology. Across neurodegenerative disorders, the impact of brain tissue in ALS research has yet to be quantified. This review aims to outline (i) how postmortem tissues from brain banks have influenced our understanding of ALS over the last 15&#x2009;years, (ii) correlate the location of dedicated brain banks with the geographical prevalence of ALS, (iii) identify the frequency of features reported from postmortem studies and (iv) propose common reporting standards for materials obtained from dedicated brain banks. A systematic review was conducted using PubMed and Web of Science databases using key words. From a total of 1439 articles, 73 articles were included in the final review, following PRISMA guidelines. Following a thematic analysis, articles were categorised into five themes; clinico-pathological (13), genetic (20), transactive response DNA binding protein 43 (TDP-43) pathology (12), non-TDP-43 neuronal pathology (nine) and extraneuronal pathology (19). Research primarily focused on the genetics of ALS, followed by protein pathology. About 63% of the brain banks were in the United States of America and United Kingdom. The location of brain banks overall aligned with the incidence of ALS worldwide with 88% of brain banks situated in Europe and North America. An overwhelming lack of consistency in reporting and replicability was observed, strengthening the need for a standardised reporting system. Overall, postmortem material from brain banks generated substantial new knowledge in areas of genetics and proteomics and supports their ongoing role as an important research tool.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Neuropathology and Applied Neurobiology published by John Wiley &amp; Sons Ltd on behalf of British Neuropathological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazumder</LastName><ForeName>Srestha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5322-5543</Identifier><AffiliationInfo><Affiliation>ForeFront Clinic, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>ForeFront Clinic, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0003-0422-8398</Identifier><AffiliationInfo><Affiliation>Frontier, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmins</LastName><ForeName>Hannah C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>ForeFront Clinic, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahoney</LastName><ForeName>Colin J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>ForeFront Clinic, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063369" MajorTopicYN="N">Knowledge Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autopsy</Keyword><Keyword MajorTopicYN="N">brain bank</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">pathology</Keyword></KeywordList><CoiStatement>All authors confirm that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>3</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35921237</ArticleId><ArticleId IdType="pmc">PMC9804699</ArticleId><ArticleId IdType="doi">10.1111/nan.12845</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eisen A. Amyotrophic lateral sclerosis: A 40&#x2010;year personal perspective. J Clin Neurosci. 2009;16(4):505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">19231200</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):807&#x2010;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2010;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakellariou D, Boniface G, Brown P. Experiences of living with motor neurone disease: a review of qualitative research. Disabil Rehabil. 2013;35(21):1765&#x2010;1773.</Citation><ArticleIdList><ArticleId IdType="pubmed">23336121</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Ahmed RM, Huynh W, et al. Pathophysiology and Treatment of Non&#x2010;motor Dysfunction in Amyotrophic Lateral Sclerosis. CNS Drugs. 2021;35(5):483&#x2010;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">33993457</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):310&#x2010;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018;17(5):385&#x2010;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose&#x2010;ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013).</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55(4):526&#x2010;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">9561981</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros&#x2010;Louis F, Gaspar C, Rouleau GA. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta (BBA) &#x2010; Molec Basis Dis. 2006;1762(11):956&#x2010;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16503123</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron. 2011;72(2):257&#x2010;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh PN, Anderton BH, Dodson A, Gallo JM, Swash M, Power DM. Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci Lett. 1988;93(2&#x2013;3):197&#x2010;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">2853844</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh PN, Whitwell H, Garofalo O, et al. Ubiquitin&#x2010;immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain. 1991;114(Pt 2):775&#x2010;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">1646064</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin. 2015;33(4):855&#x2010;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, et al. A harmonised classification system for FTLD&#x2010;TDP pathology. Acta Neuropathol. 2011;122(1):111&#x2010;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP&#x2010;43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2010;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Esopenko C, Levine B. Aging, neurodegenerative disease, and traumatic brain injury: the role of neuroimaging. J Neurotrauma. 2015;32(4):209&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321975</ArticleId><ArticleId IdType="pubmed">25192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldsman M, Egorova N. Advances in Neuroimaging for Neurodegenerative Disease. In: Beart P, Robinson M, Rattray M, Maragakis NJ, eds. Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets. Cham: Springer International Publishing; 2017:451&#x2010;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">28674993</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S. Post mortem sampling of the brain and other tissues in neurodegenerative disease. Histopathology. 2004;44(4):309&#x2010;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">15049895</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Kril JJ, McGinley C, et al. Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with ATXN 2 intermediate repeat expansions. Ann Neurol. 2016;79(2):295&#x2010;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">26599997</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Kril JJ, Fatima M, et al. TDP&#x2010;43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain. 2015;138(10):3110&#x2010;3122.</Citation><ArticleIdList><ArticleId IdType="pubmed">26231953</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlos AF, Poloni TE, Medici V, Chikhladze M, Guaita A, Ceroni M. From brain collections to modern brain banks: A historical perspective. Alzheimer's Dementia Transl Res Clin Intervent. 2019;5:52&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365388</ArticleId><ArticleId IdType="pubmed">30775417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bak TH. Motor neuron disease and frontotemporal dementia: One, two, or three diseases? Ann Indian Acad Neurol. 2010;13(Suppl 2):S81&#x2010;S88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039163</ArticleId><ArticleId IdType="pubmed">21369423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuyama Y. Presenile dementia with motor neuron disease in Japan: clinico&#x2010;pathological review of 26 cases. J Neurol Neurosurg Psychiatry. 1984;47(9):953&#x2010;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1027997</ArticleId><ArticleId IdType="pubmed">6481390</ArticleId></ArticleIdList></Reference><Reference><Citation>Samarasekera N, Salman RA&#x2010;S, Huitinga I, et al. Brain banking for neurological disorders. Lancet Neurol. 2013;12(11):1096&#x2010;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">24074724</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez H. Autopsy Rate and Physician Attitudes Toward Autopsy. Updated April. Vol. 28; 2017.</Citation></Reference><Reference><Citation>Lin M&#x2010;JP, Jowsey T, Curtis MA. Why people donate their brain to science: a systematic review. Cell Tissue Bank. 2019;20(4):447&#x2010;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6863784</ArticleId><ArticleId IdType="pubmed">31538265</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. MetaArXiv. 2020. In:2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008539</ArticleId><ArticleId IdType="pubmed">33781348</ArticleId></ArticleIdList></Reference><Reference><Citation>QGIS Geographic Information System [computer program]. Version 3.16.14. QGIS Association; 2022.</Citation></Reference><Reference><Citation>Logroscino G, Piccininni M, Marin B, et al. Global, regional, and national burden of motor neuron diseases 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(12):1083&#x2010;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234315</ArticleId><ArticleId IdType="pubmed">30409709</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinceti G, Olney N, Mandelli ML, et al. Primary progressive aphasia and the FTD&#x2010;MND spectrum disorders: clinical, pathological, and neuroimaging correlates. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):146&#x2010;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6759325</ArticleId><ArticleId IdType="pubmed">30668155</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Dammer EB, Dai J, et al. A proteomic network approach across the ALS&#x2010;FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10(1):48&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760858</ArticleId><ArticleId IdType="pubmed">29191947</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, Benatar M, Wuu J, et al. Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Mol Med. 2021;13(1):e12595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799365</ArticleId><ArticleId IdType="pubmed">33270986</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrego&#x2010;&#xc9;cija S, Turon&#x2010;Sans J, Ximelis T, et al. Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. Brain Pathol. 2021:e12942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412113</ArticleId><ArticleId IdType="pubmed">33576076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain. 2012;135(3):736&#x2010;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP, Fifita JA, Grima N, et al. Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP&#x2010;43 mice. J Neurol Neurosurg Psychiatry. 2020;91(2):162&#x2010;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">31690696</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich M, Shepheard SR, Verber N, et al. Neuropathological characterisation of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2020;46(3):279&#x2010;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">31498468</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrenberger PF, Fernando FS, Kashefi SN, et al. Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. J Neural Transm. 2015;122(7):1055&#x2010;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">25119539</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa&#x2010;Romero C, Hur J, Lunn JS, et al. Expression of microRNAs in human post&#x2010;mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol Cell Neurosci 2016;71:34&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761498</ArticleId><ArticleId IdType="pubmed">26704906</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade NS, Ramic M, Esanov R, et al. Dipeptide repeat proteins inhibit homology&#x2010;directed DNA double strand break repair in C9ORF72 ALS/FTD. Molec Neurodegener. 2020;15(1):1&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041170</ArticleId><ArticleId IdType="pubmed">32093728</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, et al. Postmortem cortex samples identify distinct molecular subtypes of als: Retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 2019;29(5):1164&#x2010;1177.e1165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedeene L, Van Schoor E, Vandenberghe R, Van Damme P, Poesen K, Thal DR. Circadian sleep/wake&#x2010;associated cells show dipeptide repeat protein aggregates in C9orf72&#x2010;related ALS and FTLD cases. Acta Neuropathol Commun. 2019;7(1):189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6889626</ArticleId><ArticleId IdType="pubmed">31791419</ArticleId></ArticleIdList></Reference><Reference><Citation>Highley JR, Kirby J, Jansweijer JA, et al. Loss of nuclear TDP&#x2010;43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones. Neuropathol Appl Neurobiol. 2014;40(6):670&#x2010;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">24750229</ArticleId></ArticleIdList></Reference><Reference><Citation>Manghera M, Ferguson&#x2010;Parry J, Douville RN. TDP&#x2010;43 regulates endogenous retrovirus&#x2010;K viral protein accumulation. Neurobiol Dis. 2016;94:226&#x2010;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">27370226</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Halliday GM, Kiernan MC, Tan RH. TDP&#x2010;43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2; gene expansions. Neurology. 2019;93(19):e1748.</Citation><ArticleIdList><ArticleId IdType="pubmed">31619481</ArticleId></ArticleIdList></Reference><Reference><Citation>Garson JA, Usher L, Al&#x2010;Chalabi A, Huggett J, Day EF, McCormick AL. Quantitative analysis of human endogenous retrovirus&#x2010;K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV&#x2010;K RNA in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2019;7(1):1&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421708</ArticleId><ArticleId IdType="pubmed">30885274</ArticleId></ArticleIdList></Reference><Reference><Citation>Montibeller L, Tan LY, Kim JK, Paul P, de Belleroche J. Tissue&#x2010;selective regulation of protein homeostasis and unfolded protein response signalling in sporadic ALS. J Cell Mol Med. 2020;24(11):6055&#x2010;6069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294118</ArticleId><ArticleId IdType="pubmed">32324341</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, Livesey MR, McDade K, et al. Dysregulation of AMPA receptor subunit expression in sporadic ALS post&#x2010;mortem brain. J Pathol. 2020;250(1):67&#x2010;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6973025</ArticleId><ArticleId IdType="pubmed">31579943</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s&#x2010;Benito P, Povedano M, Torres P, Portero&#x2010;Ot&#xed;n M, Ferrer I. Altered dynein axonemal assembly factor 1 expression in C&#x2010;Boutons in bulbar and spinal cord motor&#x2010;neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2019;78(5):416&#x2010;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">30939186</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, May S, Gr&#xe4;sser FA, et al. Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol. 2015;130(4):537&#x2010;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575390</ArticleId><ArticleId IdType="pubmed">26085200</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso R, Pisa D, Fern&#xe1;ndez&#x2010;Fern&#xe1;ndez AM, R&#xe1;bano A, Carrasco L. Fungal infection in neural tissue of patients with amyotrophic lateral sclerosis. Neurobiol Dis. 2017;108:249&#x2010;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">28888971</ArticleId></ArticleIdList></Reference><Reference><Citation>Pablo J, Banack S, Cox P, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand. 2009;120(4):216&#x2010;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">19254284</ArticleId></ArticleIdList></Reference><Reference><Citation>Saul J, Hutchins E, Reiman R, et al. Global alterations to the choroid plexus blood&#x2010;CSF barrier in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2020;8(1):92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318439</ArticleId><ArticleId IdType="pubmed">32586411</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s&#x2010;Benito P, Povedano M, Dom&#xed;nguez R, et al. Increased CXC motif chemokine ligand 12 levels in cerebrospinal fluid as a candidate biomarker in sporadic amyotrophic lateral sclerosis. Int J Mol Sci. 2020;21(22):8680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7698527</ArticleId><ArticleId IdType="pubmed">33213069</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo&#x2010;Porras F, Fern&#xe1;ndez&#x2010;Ruiz J, de Lago E. Analysis of endocannabinoid receptors and enzymes in the post&#x2010;mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotrophic Lateral Scler Frontotemporal Degeneration. 2018;19(5&#x2013;6):377&#x2010;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">29334787</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T, Iijima M, Uchihara T, et al. TDP&#x2010;43 pathology progression along the olfactory pathway as a possible substrate for olfactory impairment in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2015;74(6):547&#x2010;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">25933387</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, DeJesus&#x2010;Hernandez M, Rutherford NJ, et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011;122(6):673&#x2010;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277860</ArticleId><ArticleId IdType="pubmed">22083254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n&#x2010;S&#xe1;nchez J, Dopper EG, Cohn&#x2010;Hokke PE, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012;135(Pt 3):723&#x2010;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">22300876</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C 9ORF72 mutations. Brain. 2012;135(3):693&#x2010;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper&#x2010;Knock J, Hewitt C, Highley JR, et al. Clinico&#x2010;pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012;135(3):751&#x2010;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Vance C, Scotter EL, et al. Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiol Aging. 2015;36(3):1602.e1617&#x2010;1602.e1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357530</ArticleId><ArticleId IdType="pubmed">25499087</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Baker MC, Bieniek KF, et al. Profilin&#x2010;1 mutations are rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia. Amyotrophic Lateral Scler Frontotemporal Degeneration. 2013;14(5&#x2013;6):463&#x2010;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923463</ArticleId><ArticleId IdType="pubmed">23634771</ArticleId></ArticleIdList></Reference><Reference><Citation>Highley JR, Lorente Pons A, Cooper&#x2010;Knock J, et al. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate&#x2010;length CAG repeat expansions in Ataxin&#x2010;2 does not have 1 C 2&#x2010;positive polyglutamine inclusions. Neuropathol Appl Neurobiol. 2016;42(4):377&#x2010;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">26095883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BW, Jeong YE, Wong M, Martin LJ. DNA damage accumulates and responses are engaged in human ALS brain and spinal motor neurons and DNA repair is activatable in iPSC&#x2010;derived motor neurons with SOD1 mutations. Acta Neuropathol Commun. 2020;8(1):1&#x2010;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6995159</ArticleId><ArticleId IdType="pubmed">32005289</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa&#x2010;Romero C, Hur J, Bender DE, et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS ONE. 2012;7(12):e52672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530456</ArticleId><ArticleId IdType="pubmed">23300739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo LC, Parfenova L, Vi N, et al. Integrative gene&#x2013;tissue microarray&#x2010;based approach for identification of human disease biomarkers: application to amyotrophic lateral sclerosis. Hum Mol Genet. 2010;19(16):3233&#x2010;3253.</Citation><ArticleIdList><ArticleId IdType="pubmed">20530642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Lammich S, Mackenzie IR, et al. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62&#x2010;positive/TDP43&#x2010;negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol. 2013;125(3):413&#x2010;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23381195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AR, Selvaraj BT, Barton SK, et al. Improved detection of RNA foci in C9orf72 amyotrophic lateral sclerosis post&#x2010;mortem tissue using BaseScope&#x2122; shows a lack of association with cognitive dysfunction. Brain Commun. 2020;2(1):fcaa009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099934</ArticleId><ArticleId IdType="pubmed">32226938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosawa M, Matsumoto G, Sumikura H, et al. Serine 403&#x2010;phosphorylated p62/SQSTM1 immunoreactivity in inclusions of neurodegenerative diseases. Neurosci Res. 2016;103:64&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">26302676</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, &#x17d;upunski V, Troakes C, et al. Nuclear import impairment causes cytoplasmic trans&#x2010;activation response DNA&#x2010;binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010;133(6):1763&#x2010;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Curzio D, Gurm M, Turnbull M, et al. Pro&#x2010;inflammatory signalling upregulates a neurotoxic conotoxin&#x2010;like protein encrypted within human endogenous retrovirus&#x2010;K. Cell. 2020;9(7):1584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7407490</ArticleId><ArticleId IdType="pubmed">32629888</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Shelkovnikova T, Highley JR, et al. Gamma&#x2010;synuclein pathology in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2015;2(1):29&#x2010;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301672</ArticleId><ArticleId IdType="pubmed">25642432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos&#x2010;Campoy O, &#xc1;vila&#x2010;Polo R, Grau&#x2010;Rivera O, et al. Systematic screening of ubiquitin/p62 aggregates in cerebellar cortex expands the neuropathological phenotype of the C9orf72 expansion mutation. J Neuropathol Exp Neurol. 2018;77(8):703&#x2010;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">29889265</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132(11):2922&#x2010;2931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768659</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente Pons A, Higginbottom A, Cooper&#x2010;Knock J, et al. Oligodendrocyte pathology exceeds axonal pathology in white matter in human amyotrophic lateral sclerosis. J Pathol. 2020;251(3):262&#x2010;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">32391572</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima M, Tan R, Halliday GM, Kril JJ. Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP&#x2010;43 along axonal pathways. Acta Neuropathol Commun. 2015;3(1):1&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517552</ArticleId><ArticleId IdType="pubmed">26216351</ArticleId></ArticleIdList></Reference><Reference><Citation>De Reuck J, Devos D, Moreau C, et al. Topographic distribution of brain iron deposition and small cerebrovascular lesions in amyotrophic lateral sclerosis and in frontotemporal lobar degeneration: a post&#x2010;mortem 7.0&#x2010;T magnetic resonance imaging study with neuropathological correlates. Acta Neurol Belg. 2017;117(4):873&#x2010;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">28988390</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu L, An J, Kovalik T, Gendron T, Petrucelli L, Bowser R. Cross&#x2010;sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry. 2020;91(4):350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147184</ArticleId><ArticleId IdType="pubmed">31937582</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Foxley S, Ansorge O, et al. Methods for quantitative susceptibility and R2* mapping in whole post&#x2010;mortem brains at 7&#x2009;T applied to amyotrophic lateral sclerosis. Neuroimage. 2020;222:117216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775972</ArticleId><ArticleId IdType="pubmed">32745677</ArticleId></ArticleIdList></Reference><Reference><Citation>De Reuck J, Deramecourt V, Auger F, et al. Iron deposits in post&#x2010;mortem brains of patients with neurodegenerative and cerebrovascular diseases: a semi&#x2010;quantitative 7.0&#x2009;T magnetic resonance imaging study. Eur J Neurol. 2014;21(7):1026&#x2010;1031.</Citation><ArticleIdList><ArticleId IdType="pubmed">24698410</ArticleId></ArticleIdList></Reference><Reference><Citation>Llibre&#x2010;Guerra JJ, Lee SE, Suemoto CK, et al. A novel temporal&#x2010;predominant neuro&#x2010;astroglial tauopathy associated with TMEM106B gene polymorphism in FTLD/ALS&#x2010;TDP. Brain Pathol. 2021;31(2):267&#x2010;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7946775</ArticleId><ArticleId IdType="pubmed">33314436</ArticleId></ArticleIdList></Reference><Reference><Citation>Walt GS, Burris HM, Brady CB, et al. Chronic traumatic encephalopathy within an amyotrophic lateral sclerosis brain bank cohort. J Neuropathol Exp Neurol. 2018;77(12):1091&#x2010;1100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927868</ArticleId><ArticleId IdType="pubmed">30299493</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser LM, Kukull WA, Teylan MA, et al. The revised national Alzheimer's coordinating center's neuropathology form&#x2010;available data and new analyses. J Neuropathol Exp Neurol. 2018;77(8):717&#x2010;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6044344</ArticleId><ArticleId IdType="pubmed">29945202</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Adler CH, Sue LI, et al. Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology. 2015;35(4):354&#x2010;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593391</ArticleId><ArticleId IdType="pubmed">25619230</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Swash M. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. J Neurol Neurosurg Psychiatry. 2015;86(6):667&#x2010;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4453495</ArticleId><ArticleId IdType="pubmed">25644224</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: A proteinopathy? J Neuropathol Exp Neurol. 2005;64(8):649&#x2010;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">16106213</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K. Motor neurone disease. Postgrad Med J. 2002;78(923):513&#x2010;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1742493</ArticleId><ArticleId IdType="pubmed">12357010</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron. 2011;72(2):245&#x2010;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice JR, Gregory&#x2010;Evans CY, Shaw CA. Animal models of amyotrophic lateral sclerosis: A comparison of model validity. Neural Regen Res. 2018;13(12):2050&#x2010;2054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Bhattacharyya A. Human models are needed for studying human neurodevelopmental disorders. Am J Hum Genet. 2018;103(6):829&#x2010;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288051</ArticleId><ArticleId IdType="pubmed">30526865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">29577886</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol. 2015;69:5.67.61&#x2010;65.67.21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP&#x2010;43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427&#x2010;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinone SE, Ghadge GD, Ostrow LW, Roos RP, Green WN. S&#x2010;acylation of SOD1, CCS, and a stable SOD1&#x2010;CCS heterodimer in human spinal cords from ALS and non&#x2010;ALS subjects. Sci Rep. 2017;7(1):1&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5264640</ArticleId><ArticleId IdType="pubmed">28120938</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Martinez&#x2010;Lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP&#x2010;43 proteinopathies. Arch Neurol. 2009;66(2):180&#x2010;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774117</ArticleId><ArticleId IdType="pubmed">19204154</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE. TDP&#x2010;43 proteinopathy and ALS: Insights into disease mechanisms and therapeutic targets. Neurotherapeutics. 2015;12(2):352&#x2010;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, Rowe DB, Kiernan MC, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):595&#x2010;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104&#x2010;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Puigdomenech&#x2010;Poch M, Mart&#xed;nez&#x2010;Muriana A, Andr&#xe9;s&#x2010;Benito P, Ferrer I, Chun J, L&#xf3;pez&#x2010;Vales R. Dual role of lysophosphatidic acid receptor 2 (LPA2) in amyotrophic lateral sclerosis. Front Cell Neurosci. 2021;15:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026865</ArticleId><ArticleId IdType="pubmed">33841099</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundogdu B, Al&#x2010;Lahham T, Kadlubar F, Spencer H, Rudnicki SA. Racial differences in motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1&#x2013;2):114&#x2010;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264350</ArticleId><ArticleId IdType="pubmed">24067242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtman L, Jordan H, Wagner L, Horton DK, Kaye W. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1&#x2013;2):65&#x2010;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389704</ArticleId><ArticleId IdType="pubmed">25482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Higashihara M, Sobue G, et al. ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology. 2020;94(15):e1657&#x2010;e1663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251515</ArticleId><ArticleId IdType="pubmed">32071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7:12408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer&#x2010;Aronsten B, Sheedy D, McCrossin T, Kril J. An international survey of brain banking operation and characterisation practices. Biopreserv Biobanking. 2016;14(6):464&#x2010;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5180078</ArticleId><ArticleId IdType="pubmed">27399803</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7(6):557&#x2010;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummins RO, Chamberlain DA, Abramson NS, et al. Recommended guidelines for uniform reporting of data from out&#x2010;of&#x2010;hospital cardiac arrest: the Utstein Style. A statement for health professionals from a task force of the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, and the Australian Resuscitation Council. Circulation. 1991;84(2):960&#x2010;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">1860248</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis PT, Hayes GM, Costello H, Whitfield DR. Brains for dementia research: The importance of cohorts in brain banking. Neurosci Bull. 2019;35(2):289&#x2010;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426925</ArticleId><ArticleId IdType="pubmed">30604278</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al. The PRO&#x2010;ACT database. Neurology. 2014;83(19):1719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging&#x2013;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123(1):1&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>